Home >> Pharmaceuticals >> Food & Beverage >>

Biological E. Limited - Product Pipeline Review - 2015

Published: Aug-2015 | Format: PDF | Global Markets Direct | Number of pages: 29 | Code: MRS - 35145

Biological E. Limited - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Biological E. Limited - Product Pipeline Review - 2015’, provides an overview of the Biological E. Limited’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Biological E. Limited’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Biological E. Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Biological E. Limited’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Biological E. Limited’s pipeline products

Reasons to buy

- Evaluate Biological E. Limited’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Biological E. Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Biological E. Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Biological E. Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biological E. Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Biological E. Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Biological E. Limited Snapshot 5
Biological E. Limited Overview 5
Key Information 5
Key Facts 5
Biological E. Limited - Research and Development Overview 6
Key Therapeutic Areas 6
Biological E. Limited - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Biological E. Limited - Pipeline Products Glance 14
Biological E. Limited - Late Stage Pipeline Products 14
Phase III Products/Combination Treatment Modalities 14
Biological E. Limited - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Biological E. Limited - Unknown Stage Pipeline Products 16
Unknown Products/Combination Treatment Modalities 16
Biological E. Limited - Drug Profiles 17
(diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent)) vaccine 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
(diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent)) vaccine 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
meningococcal [serotypes A, C, W, Y] vaccine 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
rotavirus (tetravalent) vaccine 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
measles + rubella vaccine 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
pneumococcal vaccine 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Biological E. Limited - Pipeline Analysis 23
Biological E. Limited - Pipeline Products by Target 23
Biological E. Limited - Pipeline Products by Route of Administration 24
Biological E. Limited - Pipeline Products by Molecule Type 25
Biological E. Limited - Dormant Projects 26
Biological E. Limited - Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 28
Disclaimer 29

List of Tables
Biological E. Limited, Key Information 5
Biological E. Limited, Key Facts 5
Biological E. Limited - Pipeline by Indication, 2015 7
Biological E. Limited - Pipeline by Stage of Development, 2015 9
Biological E. Limited - Monotherapy Products in Pipeline, 2015 10
Biological E. Limited - Combination Treatment Modalities in Pipeline, 2015 11
Biological E. Limited - Partnered Products in Pipeline, 2015 12
Biological E. Limited - Partnered Products/ Combination Treatment Modalities, 2015 13
Biological E. Limited - Phase III, 2015 14
Biological E. Limited - Preclinical, 2015 15
Biological E. Limited - Unknown, 2015 16
Biological E. Limited - Pipeline by Target, 2015 23
Biological E. Limited - Pipeline by Route of Administration, 2015 24
Biological E. Limited - Pipeline by Molecule Type, 2015 25
Biological E. Limited - Dormant Developmental Projects,2015 26
Biological E. Limited, Other Locations 27

List of Figures
Biological E. Limited - Pipeline by Top 10 Indication, 2015 7
Biological E. Limited - Pipeline by Stage of Development, 2015 9
Biological E. Limited - Monotherapy Products in Pipeline, 2015 10
Biological E. Limited - Combination Treatment Modalities in Pipeline, 2015 11
Biological E. Limited - Pipeline by Top 10 Target, 2015 23
Biological E. Limited - Pipeline by Top 10 Molecule Type, 2015 25

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

Single User | $(USD)1500 View Pricing